Literature DB >> 19064572

Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women.

Rachel T Palmieri1, Melanie A Wilson, Edwin S Iversen, Merlise A Clyde, Brian Calingaert, Patricia G Moorman, Charles Poole, A Rebecca Anderson, Stephanie Anderson, Hoda Anton-Culver, Jonathan Beesley, Estrid Hogdall, Wendy Brewster, Michael E Carney, Xiaoqing Chen, Georgia Chenevix-Trench, Jenny Chang-Claude, Julie M Cunningham, Richard A Dicioccio, Jennifer A Doherty, Douglas F Easton, Christopher K Edlund, Simon A Gayther, Aleksandra Gentry-Maharaj, Ellen L Goode, Marc T Goodman, Susanne Kruger Kjaer, Claus K Hogdall, Michael P Hopkins, Eric L Jenison, Jan Blaakaer, Galina Lurie, Valerie McGuire, Usha Menon, Kirsten B Moysich, Roberta B Ness, Celeste Leigh Pearce, Paul D P Pharoah, Malcolm C Pike, Susan J Ramus, Mary Anne Rossing, Honglin Song, Keith Y Terada, David Vandenberg, Robert A Vierkant, Shan Wang-Gohrke, Penelope M Webb, Alice S Whittemore, Anna H Wu, Argyrios Ziogas, Andrew Berchuck, Joellen M Schildkraut.   

Abstract

Over 22,000 cases of ovarian cancer were diagnosed in 2007 in the United States, but only a fraction of them can be attributed to mutations in highly penetrant genes such as BRCA1. To determine whether low-penetrance genetic variants contribute to ovarian cancer risk, we genotyped 1,536 single nucleotide polymorphisms (SNP) in several candidate gene pathways in 848 epithelial ovarian cancer cases and 798 controls in the North Carolina Ovarian Cancer Study (NCO) using a customized Illumina array. The inflammation gene interleukin-18 (IL18) showed the strongest evidence for association with epithelial ovarian cancer in a gene-by-gene analysis (P = 0.002) with a <25% chance of being a false-positive finding (q value = 0.240). Using a multivariate model search algorithm over 11 IL18 tagging SNPs, we found that the association was best modeled by rs1834481. Further, this SNP uniquely tagged a significantly associated IL18 haplotype and there was an increased risk of epithelial ovarian cancer per rs1834481 allele (odds ratio, 1.24; 95% confidence interval, 1.06-1.45). In a replication stage, 12 independent studies from the Ovarian Cancer Association Consortium (OCAC) genotyped rs1834481 in an additional 5,877 cases and 7,791 controls. The fixed effects estimate per rs1834481 allele was null (odds ratio, 0.99; 95% confidence interval, 0.94-1.05) when data from the 12 OCAC studies were combined. The effect estimate remained unchanged with the addition of the initial North Carolina Ovarian Cancer Study data. This analysis shows the importance of consortia, like the OCAC, in either confirming or refuting the validity of putative findings in studies with smaller sample sizes. (Cancer Epidemiol Biomarkers Prev 2008;17(12):3567-72).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19064572      PMCID: PMC2664299          DOI: 10.1158/1055-9965.EPI-08-0548

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  33 in total

Review 1.  Review: cytokine involvement in ovarian processes.

Authors:  P F Terranova; V M Rice
Journal:  Am J Reprod Immunol       Date:  1997-01       Impact factor: 3.886

2.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

3.  Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations.

Authors:  V McGuire; A Felberg; M Mills; K L Ostrow; R DiCioccio; E M John; D W West; A S Whittemore
Journal:  Am J Epidemiol       Date:  2004-10-01       Impact factor: 4.897

Review 4.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

5.  Polymorphisms in DNA repair genes and epithelial ovarian cancer risk.

Authors:  Annika Auranen; Honglin Song; Christy Waterfall; Richard A Dicioccio; Bettina Kuschel; Susanne K Kjaer; Estrid Hogdall; Claus Hogdall; John Stratton; Alice S Whittemore; Douglas F Easton; Bruce A J Ponder; Karen L Novik; Alison M Dunning; Simon Gayther; Paul D P Pharoah
Journal:  Int J Cancer       Date:  2005-11-20       Impact factor: 7.396

Review 6.  Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction.

Authors:  L L Espey
Journal:  Biol Reprod       Date:  1994-02       Impact factor: 4.285

7.  Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer.

Authors:  Abigail W Bushley; Robert Ferrell; Katharine McDuffie; Keith Y Terada; Michael E Carney; Pamela J Thompson; Lynne R Wilkens; Ko-Hui Tung; Roberta B Ness; Marc T Goodman
Journal:  Gynecol Oncol       Date:  2004-12       Impact factor: 5.482

Review 8.  Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies.

Authors:  Tomas Riman; Staffan Nilsson; Ingemar R Persson
Journal:  Acta Obstet Gynecol Scand       Date:  2004-09       Impact factor: 3.636

9.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group.

Authors:  A S Whittemore; R Harris; J Itnyre
Journal:  Am J Epidemiol       Date:  1992-11-15       Impact factor: 4.897

10.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group.

Authors:  A S Whittemore; R Harris; J Itnyre
Journal:  Am J Epidemiol       Date:  1992-11-15       Impact factor: 4.897

View more
  7 in total

1.  Genetic variation in Th1/Th2 pathway genes and risk of non-Hodgkin lymphoma: a pooled analysis of three population-based case-control studies.

Authors:  Qing Lan; Sophia S Wang; Idan Menashe; Bruce Armstrong; Yawei Zhang; Patricia Hartge; Mark P Purdue; Theodore R Holford; Lindsay M Morton; Anne Kricker; James R Cerhan; Andrew Grulich; Wendy Cozen; Shelia H Zahm; Meredith Yeager; Claire M Vajdic; Maryjean Schenk; Brian Leaderer; Jeff Yuenger; Richard K Severson; Nilanjan Chatterjee; Stephen J Chanock; Tongzhang Zheng; Nathaniel Rothman
Journal:  Br J Haematol       Date:  2011-03-21       Impact factor: 6.998

Review 2.  Targeted immune therapy of ovarian cancer.

Authors:  Keith L Knutson; Lavakumar Karyampudi; Purushottam Lamichhane; Claudia Preston
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

3.  Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.

Authors:  Catherine M Phelan; Ya-Yu Tsai; Ellen L Goode; Robert A Vierkant; Brooke L Fridley; Jonathan Beesley; Xiao Qing Chen; Penelope M Webb; Stephen Chanock; Daniel W Cramer; Kirsten Moysich; Robert P Edwards; Jenny Chang-Claude; Montserrat Garcia-Closas; Hannah Yang; Shan Wang-Gohrke; Rebecca Hein; Adele C Green; Jolanta Lissowska; Michael E Carney; Galina Lurie; Lynne R Wilkens; Roberta B Ness; Celeste Leigh Pearce; Anna H Wu; David J Van Den Berg; Daniel O Stram; Kathryn L Terry; David C Whiteman; Alice S Whittemore; Richard A DiCioccio; Valerie McGuire; Jennifer A Doherty; Mary Anne Rossing; Hoda Anton-Culver; Argyrios Ziogas; Claus Hogdall; Estrid Hogdall; Susanne Krüger Kjaer; Jan Blaakaer; Lydia Quaye; Susan J Ramus; Ian Jacobs; Honglin Song; Paul D P Pharoah; Edwin S Iversen; Jeffrey R Marks; Malcolm C Pike; Simon A Gayther; Julie M Cunningham; Marc T Goodman; Joellen M Schildkraut; Georgia Chenevix-Trench; Andrew Berchuck; Thomas A Sellers
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

Review 4.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

5.  Genetics and women's health issues--the commitment of EMS to women scientists and gender-associated disease topics.

Authors:  Kristine L Witt; Patricia G Moorman; Olga Kovalchuk; Nina Holland; Gladys Block; Paul R Andreassen
Journal:  Environ Mol Mutagen       Date:  2010 Oct-Dec       Impact factor: 3.216

6.  Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.

Authors:  Ioannis Alagkiozidis; Andrea Facciabene; Carmine Carpenito; Fabian Benencia; Zdenka Jonak; Sarah Adams; Richard G Carroll; Phyllis A Gimotty; Rachel Hammond; Gwen-äel Danet-Desnoyers; Carl H June; Daniel J Powell; George Coukos
Journal:  J Transl Med       Date:  2009-12-10       Impact factor: 5.531

7.  Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer.

Authors:  Lydia Quaye; Jonathan Tyrer; Susan J Ramus; Honglin Song; Eva Wozniak; Richard A DiCioccio; Valerie McGuire; Estrid Høgdall; Claus Høgdall; Jan Blaakaer; Ellen L Goode; Joellen M Schildkraut; Douglas F Easton; Susanne Krüger-Kjaer; Alice S Whittemore; Simon A Gayther; Paul D P Pharoah
Journal:  PLoS One       Date:  2009-06-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.